Drug intelligence / Profile preview

CF602

Development stage: Preclinical
Lead developer: Can-Fite BioPharma
Modality: Small Molecules
Administration: Oral, Topical

Overview

CF602 is a small molecule drug developed by Can-Fite BioPharma. It is an A3 adenosine receptor agonist, part of the company's pipeline of small molecule drugs targeting the A3 adenosine receptor. The drug is currently in preclinical development for erectile dysfunction and is also being developed for inflammation and sexual dysfunction.

Targets

ADORA3 (Adenosine A3 receptor)

Beyond the preview

Go deeper on CF602.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CF602.

Explore the full profile